NCT05621330View on ClinicalTrials.gov

Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia

PHASE3CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

October 18, 2019

Primary Completion Date

December 13, 2021

Study Completion Date

December 16, 2021

Conditions
Primary Immune Thrombocytopenia
Interventions
DRUG

QL0911

The study in a 2:1 randomization ratio(144 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

DRUG

Placebo comparator

The study in a 2:1 randomization ratio(72 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

Trial Locations (1)

Unknown

Qilu Hospital of Shandong University, Shandong

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT05621330 - Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia | Biotech Hunter | Biotech Hunter